Cytomegalovirus, aging, and HIV: A perfect storm

AIDS Reviews

Volumn 14, Issue 3, 2012, Pages 159-167

  Barrett, Lisa ^a   Fowke, Keith R ^b,c   Grant, Michael D ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Aging; Cardiovascular disease; CMV; Cognitive impairment; HIV; Immune risk phenotype; Immune senescence; Inflammation

Indexed keywords

ANTIRETROVIRUS AGENT; T LYMPHOCYTE RECEPTOR;

AGING; ATHEROSCLEROSIS; CD8+ T LYMPHOCYTE; COMORBIDITY; CYTOMEGALOVIRUS; DISEASE COURSE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; INFECTION RISK; INFECTION SENSITIVITY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGED; AGING; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELL AGING; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; FEMALE; HIV-1; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 84864718204     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Barton E, White D, Cathelyn J, et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature. 2007;447:326-9. (Pubitemid 46788830)
2. Kinney J, Onorato I, Stewart J, et al. Cytomegaloviral infection and disease. J Infect Dis. 1985;151:772-4. (Pubitemid 15094591)
3. Onorato I, Morens D, Martone W, et al. Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis. 1985;7:479-97.
4. Naeger D, Martin J, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5:e8886.
5. Samaras K, Gan S, Peake P, et al. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity. 2009;17:53-9. (Pubitemid 50331903)
6. Deeks S. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118-23.
7. Ferguson F, Wikby A, Maxson P, et al. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci. 1995;50:B378-82.
8. Wayne S, Rhyne R, Garry P, et al. Cell-mediated immunity as a predictor of morbidity and mortality in subjects over 60. J Gerontol. 1990;45:M45-8. (Pubitemid 20104835)
9. Olsson J, Wikby A, Johansson B, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187-201. (Pubitemid 32115413)
10. Hadrup S, Strindhall J, Kollgaard T, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirusspecific T cells in the very elderly. J Immunol. 2006;176:2645-53. (Pubitemid 43201717)
11. + T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol. 2003;23:247-57.
12. + T-cell subsets in the elderly. Hum Immunol. 2007;68:86-90.
13. + T lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445-53.
14. Anasetti C, Tan P, Hansen J, et al. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen. J Exp Med. 1990;172:1691-700.
15. June C, Ledbetter J, Gillespie M, et al. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol. 1987;7:4472-81. (Pubitemid 17166404)
16. + T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol. 1994;29:601-9.
17. Effros R. Replicative senescence of CD8+ T cells: effect on human ageing. Exp Gerontol. 2004;39:517-24. (Pubitemid 38402077)
18. Brenchley J, Karandikar N, Betts M, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711-20. (Pubitemid 36857634)
19. Chattopadhyay P, Betts M, Price D, et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol. 2009;85:88-97.
20. +T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005;79:3675-83.
21. + subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol. 1999;29:2908-15.
22. Pawelec G, Gouttefangeas C. T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence? Aging Clin Exp Res. 2006;18:171-3. (Pubitemid 43833639)
23. Strindhall J, Nilsson B, Lofgren S, et al. No immune risk profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol. 2007;42:753-61. (Pubitemid 47058867)
24. Posnett D, Sinha R, Kabak S, et al. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med. 1994;179:609-18.
25. Jeune B. Living longer - but better? Aging Clin Exp Res. 2002;14:72-93. (Pubitemid 34752142)
26. + T cells after infection. Nat Immunol. 2002;3:619-26.
27. + T cells and the role of IFN-gamma receptor in immune regulation. J Immunol. 2004;172:1491-500.
28. Zajac A, Blattman J, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-13. (Pubitemid 29028493)
29. Tarazona R, DelaRosa O, Alonso C, et al. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev. 2000;121:77-88. (Pubitemid 32115402)
30. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8+ T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169:1984-92. (Pubitemid 34857662)
31. Karrer U, Sierro S, Wagner M, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170:2022-9. (Pubitemid 36197423)
32. Moss P, Khan N. CD8+ T-cell immunity to cytomegalovirus. Hum Immunol. 2004;65:456-64.
33. Stowe R, Kozlova E, Yetman D, et al. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. 2007;42:563-70. (Pubitemid 46756093)
34. Ouyang Q, Wagner W, Wikby A, et al. Compromised interferon gamma production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? Eur Cytokine Netw. 2002;13:392-4. (Pubitemid 36174092)
35. Wikby A, Maxson P, Olsson J, et al. Changes in CD8+ and CD4+ lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev. 1998;102:187-98. (Pubitemid 28353538)
36. DelaRosa O, Pawelec G, Peralbo E, et al. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology. 2006;7:471-81.
37. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity. 2006;24:491-4. (Pubitemid 43728154)
38. Pawelec G, Koch S, Franceschi C, et al. Human immunosenescence: does it have an infectious component? Ann N Y Acad Sci. 2006;1067:56-65. (Pubitemid 43806310)
39. Simanek A, Dowd J, Aiello A. Persistent pathogens linking socioeconomic position and cardiovascular disease in the US. Int J Epidemiol. 2009;38:775-87.
40. Simanek A, Dowd J, Pawelec G, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6:e16103.
41. Wikby A, Johansson B, Ferguson F, et al. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol. 1994;29:531-41. (Pubitemid 24294545)
42. Pawelec G. Immunosenescence and vaccination. Immun Ageing. 2005;2:16.
43. Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination - an impact of immunosenescence. Vaccine. 2003;21:3826-36. (Pubitemid 37338210)
44. den Elzen W, Vossen A, Cools H, et al. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine. 2011;29:4869-74.
45. Moro-Garcia M, Alonso-Arias R, Lopez-Vazquez A, et al. Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age. 2012;34:479-95.
46. Effros R. From Hayflick to Walford: the role of T cell replicative senescence in human aging. Exp Gerontol. 2004;39:885-90. (Pubitemid 38798525)
47. + T cells: potential effects on cancer immune surveillance and immunotherapy. Cancer Immunol Immunother. 2004;53:925-33.
48. Wikby A, Nilsson B, Forsey R, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev. 2006;127:695-704. (Pubitemid 43949280)
49. Strandberg T, Pitkala K, Linnavuori K, et al. Cognitive impairment and infectious burden in the elderly. Arch Gerontol Geriatr Suppl. 2004:419-23. (Pubitemid 38822894)
50. Strandberg T, Pitkala K, Linnavuori K, et al. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke. 2003;34:2126-31. (Pubitemid 37099824)
51. Roberts B, Cech I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. South Med J. 2005;98:686-92. (Pubitemid 41061653)
52. Aiello A, Haan M, Blythe L, et al. The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc. 2006;54:1046-54. (Pubitemid 43992540)
53. Vescovini R, Biasini C, Telera A, et al. Intense antiextracellular adaptive immune response to human cytomegalovirus in very old subjects with impaired health and cognitive and functional status. J Immunol. 2010;184:3242-9.
54. Xie F, Hu Y, Magee L, et al. An association between cytomegalovirus infection and pre-eclampsia: a case-control study and data synthesis. Acta Obstet Gynecol Scand. 2010;89:1162-7.
55. Margolick J, Gange S, Detels R, et al. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr. 2006;42:620-6. (Pubitemid 44162434)
56. Shepp D, Moses J, Kaplan M. Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:460-8. (Pubitemid 26135083)
57. Lieberman J, Shankar P, Manjunath N, et al. Dressed to kill? A review of why antiviral CD8+ T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood. 2001;98:1667-77.
58. Robbins G, Spritzler J, Chan E, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48:350-61.
59. Appay V, Almeida J, Sauce D, et al. Accelerated immune senescence and HIV-1 infection. Exp Gerontol. 2007;42:432-7. (Pubitemid 46561182)
60. Heaton R, Clifford D, Franklin D, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-96.
61. Heaton R, Franklin D, Ellis R, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
62. Appay V, Fastenackels S, Katlama C, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011;25:1813-22.
63. Botto S, Streblow D, DeFilippis V, et al. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood. 2011;17:352-61.
64. Dumortier J, Streblow D, Moses A, et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol. 2008;82:6524-35. (Pubitemid 351875129)
65. Bolovan-Fritts C, Trout R, Spector S. High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood. 2007;110:1857-63. (Pubitemid 47443897)
66. Bolovan-Fritts C, Spector S. Endothelial damage from cytomegalovirusspecific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood. 2008;111:175-82.
67. +T cells and CMV-induced T cell immunopathology in HIV-associated atherosclerosis. AIDS. 2012;26:805-14.
68. Hsue P, Hunt P, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275-83. (Pubitemid 44789529)
69. Caposio P, Orloff S, Streblow D. The role of cytomegalovirus in angiogenesis. Virus Res. 2011;157:204-11.
70. Nieto F, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation. 1996;94:922-7. (Pubitemid 26292841)
71. Baker D, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479:232-6.
72. Koide J, Engleman E. Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones. J Immunol. 1990;144:32-40. (Pubitemid 20030454)
73. Autran B, Leblond V, Sadat-Sowti B, et al. A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood. 1991;77:2237-41.
74. + lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol. 1991;21:737-41.
75. Damle N, Engleman E. Antigen-specific suppressor T lymphocytes in man. Clin Immunol Immunopathol. 1989;53:S17-24. (Pubitemid 19276600)
76. Jesser R, Li S, Weinberg A. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation. Virology. 2006;352:408-17.
77. +CD27-CD28- T cells. Virology. 2010;398:158-67.
78. Schwele S, Fischer A, Brestrich G, et al. Cytomegalovirus-specific regulatory and effector T cells share TCR clonality - possible relation to repetitive CMV infections. Am J Transplant. 2011;12:669-81.
79. + T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474-83.
80. Leng S, Li H, Xue Q, et al. Association of detectable cytomegalovirus (CMV) DNA in monocytes rather than positive CMV IgG serology with elevated neopterin levels in community-dwelling older adults. Exp Gerontol. 2011;46:679-84.
81. Leng S, Qu T, Semba R, et al. Relationship between cytomegalovirus (CMV) IgG serology, detectable CMV DNA in peripheral monocytes, and CMV pp65(495-503)-specific CD8+ T cells in older adults. Age. 2011;33:607-14.
82. El Amari E, Combescure C, Yerly S, et al. Clinical relevance of cytomegalovirus viraemia. HIV Med. 2011;12:394-402.
83. Hansen S, Ford J, Lewis M, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473:523-7.